Juventas Therapeutics is a private, clinical-stage biotechnology company focused on developing innovative non-viral gene therapies. These therapies are designed to activate the body's natural repair mechanisms, specifically through the use of stromal cell-derived factor 1 (SDF-1), a signaling protein that recruits stem cells to promote tissue repair. The company's flagship product candidate, JVS-100, leverages this approach to address a broad range of disease states.

Juventas operates in the regenerative medicine market, targeting conditions that require tissue repair and regeneration. Its clients primarily include healthcare providers and patients suffering from diseases that can benefit from advanced gene therapy solutions.

The business model is centered around the development and clinical testing of its proprietary therapies, with the aim of eventually bringing these treatments to market. Revenue generation will likely come from the commercialization of its therapies, either through direct sales or partnerships with larger pharmaceutical companies.

Keywords: regenerative medicine, gene therapy, SDF-1, stem cells, tissue repair, clinical-stage, biotechnology, non-viral, innovative therapies, healthcare.